Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | EPOR | P19235 | 3/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31259077 | 0.87 | EPOR (0.40) | GSRRNPEPEPORCPB2MMP2 | |
| SCHEMBL4482909 | 0.82 | EPOR (0.34) | GSREPOR | |
| SCHEMBL4566397 | 0.76 | — | — | |
| SCHEMBL4024390 | 0.70 | GSR (0.47) | GSRRNPEPCPB2CPB1 | |
| SCHEMBL28184620 | 0.68 | NPSR1 (0.33) | — | |
| SCHEMBL6205350 | 0.68 | GSR (0.39) | GSR | |
| SCHEMBL28720460 | 0.66 | CPB2 (0.44) | GSRRNPEPEPORCPB2CPB1 | |
| SCHEMBL4629185 | 0.66 | MMP2 (0.40) | GSRRNPEPEPORCPB2MMP2 | |
| SCHEMBL4629186 | 0.66 | MMP2 (0.40) | GSRRNPEPEPORCPB2MMP2 | |
| SCHEMBL14228039 | 0.66 | GSR (0.50) | GSRRNPEPCPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | GSR 4414/4885RNPEP 4353/4885EPOR 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.